Avalyn Pharma Quarterly Balance Sheet
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalyn Pharma financial position
As of Jun 30, 2026, Avalyn Pharma reported total assets of $425.4 million against total liabilities of $27.1 million. Shareholders' equity stood at $398.3 million, or 93.6% of assets. The company held $264.2 million in cash and equivalents against $14.8 million of debt, a net cash position of $249.4 million.
The current ratio (current assets divided by current liabilities) was 33.12, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.04.
Summary generated from market data by MetaCap's automated system. Methodology
Avalyn Pharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 264.20M | 92.31M | 61.30M | 28.80M |
| Short-Term Investments | 88.23M | 30.82M | — | — |
| Total Current Assets | 357.99M | 129.99M | — | — |
| Property, Plant & Equipment | 1.21M | 1.26M | — | — |
| Long-Term Investments | 61.10M | — | — | — |
| Total Assets | 425.45M | 135.66M | — | — |
| Accounts Payable | 2.65M | 3.15M | — | — |
| Total Current Liabilities | 10.81M | 11.79M | — | — |
| Long-Term Debt | 14.80M | 14.81M | — | — |
| Total Liabilities | 27.10M | 27.69M | — | — |
| Shareholders' Equity | 398.35M | -264.25M | -194.39M | -191.57M |
| Retained Earnings | -321.17M | -292.23M | — | — |
| Total Debt | 14.80M | 14.81M | — | — |
| Net Cash (Debt) | 337.62M | 108.32M | 61.30M | 28.80M |
| Shares Outstanding | 44.33M | 1.23M | — | — |
This table shows 4 quarterly periods of Avalyn Pharma's balance sheet, from Q2 2026 back to Q? 2025, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow AVLN's reporting calendar. What is a balance sheet?